Earnings Preview — 2814 total
Zenas BioPharma heads into its May 15 results with one of the most aggressive short-interest builds in recent memory — and a CEO who has been buying into the decline with his own cash. Short sellers have dramatically…
Legacy Education Inc. reports today with the stock up 11% on the week — yet the short-selling community is barely engaged. Short interest is negligible. It registers just 0.53% of the free float, a level so thin it…
SCHMID Group heads into its May 18 earnings report with short sellers charging in even as the stock rallies — a pointed divergence that sets up a tense read. Short interest has jumped 55% in a single week to roughly…
AIRJ heads into its Q1 2026 earnings report today with a stock that has rallied hard and short sellers quietly building positions into the move. The price action sets a complicated stage. AIRJ has climbed 31% in a…
XBP Global Holdings reports Q1 2026 results today with two stories running simultaneously: a borrow market under unexpected pressure and a board-level process that may define the company's future more than any…
Adlai Nortye Ltd. goes into today's earnings release carrying one of the most extreme short-positioning profiles in the biotech universe. Short sellers have piled in hard. SI % of free float has ballooned to nearly 8%…
SBIG reports earnings today against a backdrop of steep price deterioration and almost no short-side pressure — making this a print defined almost entirely by fundamental survival rather than positioning dynamics. The…
Shuttle Pharmaceuticals Holdings heads into today's earnings with one of the most contradictory lending setups in its recent history — borrow costs at extreme levels, yet short sellers rapidly covering. The…
Faraday Future Intelligent Electric heads into its May 15 earnings report as one of the most heavily shorted small-cap names in the US auto sector — with the borrow market nearly exhausted and short sellers showing no…
Tango Therapeutics heads into its May 15 earnings print having already moved the market — the question now is whether the fundamental story has caught up with the repositioning. The most striking shift in positioning…
Tempest Therapeutics heads into a complex moment: the Q1 print has already landed, and it's a miss — but the stock rose 13.6% the day before, and short sellers have been trimming exposure throughout. The headline print…
Greenidge Generation Holdings reports today with short sellers at their most aggressive in over a month — yet the lending market tells a more measured story than the headline number suggests. Short interest has climbed…
HCW Biologics Inc. reports today with one of the most aggressively shorted lending setups in the small-cap biotech universe — a rare combination of sky-high short interest, near-maximum cost to borrow, and a lending…
DLocal heads into its May 15 results day with short sellers meaningfully more committed than they were a month ago — and options traders growing more cautious alongside them. Short interest climbed to 8.4% of the free…
The Glimpse Group, Inc. carries a consistent pattern of sharp post-earnings declines into today's print, and the positioning data does little to suggest this time feels different. The earnings history is the starkest…
AVX heads into tonight's earnings release with short sellers in full retreat — a sharp reversal from extreme positioning just weeks ago. The borrow market tells the clearest story. Short interest collapsed 67% over the…
NXGL heads into its May 15 earnings report as a micro-cap medical device company with a lending market that tells a surprisingly relaxed story — even as short interest has surged sharply in recent weeks. The most…
IDAI heads into its Q1 2026 results tonight carrying a visible contradiction: revenue grew 39% year-over-year, yet the company still missed both its EPS and sales estimates. The numbers filed after the close tell the…
Leslie's, Inc. heads into Monday's May 18 event carrying one of the most violent short-squeeze setups in the specialty retail space right now. The stock erupted 145% in a single session after the company's Q2 2026…
Nurix Therapeutics heads into today's earnings print as one of the more heavily shorted names in clinical-stage biotech, with short sellers retaining a firm grip on the stock. Short interest is running at roughly 21.9%…
